Search

Your search keyword '"Procopio G."' showing total 900 results

Search Constraints

Start Over You searched for: Author "Procopio G." Remove constraint Author: "Procopio G."
900 results on '"Procopio G."'

Search Results

2. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

3. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

4. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study

5. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

6. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

7. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

11. Does multiparametric (mp) MRI and MRI-informed biopsy improve risk allocation of men at inclusion in active surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial

12. Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years’ experience

13. 12P Do retroperitoneal extragonadal germ cell tumours (pR-GCT) exist? Evaluation of treatment outcomes of an international retrospective collaboration (PRIMERE study-IGG05)

14. Primary retroperitoneal germ-cell tumors (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)

15. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma

16. Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study

17. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial

18. 26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

19. Grade reclassification during active surveillance in low risk prostate cancer men selected with an MRI-informed biopsy

20. Pretreatment with P2Y12 inhibitors and relationship with clinical outcomes in NSTEMI: Analysis of 2 Argentinian registries

21. 2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

24. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

25. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

26. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

27. Targeted treatments in advanced renal cell carcinoma: focus on axitinib

28. 157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

29. 1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

30. 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)

31. LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

32. 1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)

35. 2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)

36. 1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis

38. 1624P Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study

39. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

40. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Catalog

Books, media, physical & digital resources